Results 61 to 70 of about 5,794,088 (264)

How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

open access: yes, 2011
Given that cardiovascular safety liabilities remain a major cause of drug attrition during preclinical and clinical development, adverse drug reactions, and post-approval withdrawal of medicines, the Medical Research Council Centre for Drug Safety ...
N Roome   +86 more
core   +1 more source

Investigation of safety and efficacy of febantel and fenbendazole in fish and exposure assessment

open access: yesApplied Biological Chemistry
Fish are susceptible to blood-sucking parasite infections, which cause severe anemia, dyspnea, and ultimately death. However, veterinary drugs available for fish to treat such infectious diseases are lacking; thus, livestock drugs have been repurposed as
Min Ji Kim   +3 more
doaj   +1 more source

Papyrus: a large-scale curated dataset aimed at bioactivity predictions

open access: yesJournal of Cheminformatics, 2023
With the ongoing rapid growth of publicly available ligand–protein bioactivity data, there is a trove of valuable data that can be used to train a plethora of machine-learning algorithms.
O. J. M. Béquignon   +5 more
doaj   +1 more source

Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system

open access: yesFEBS Letters, EarlyView.
Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley   +1 more source

Drug-drug interactions in repeat prescriptions at village dispensaries (bereg) in Malta [PDF]

open access: yes, 2013
Inappropriate treatments and drug-drug interactions (DDIs) are known to occur in settings where repeat prescriptions are issued. In view of this, a study was carried out to document any such problematic drug prescribing and propose changes that would
Bugeja, Anton
core  

Degradation mechanism of the von Willebrand factor A2 domain by nattokinase

open access: yesFEBS Letters, EarlyView.
Nattokinase, a natto‐derived protease, exhibits potent antithrombotic effects. This study demonstrates that nattokinase directly cleaves the von Willebrand factor (vWF) A2 domain in vitro. Unlike the native regulator ADAMTS13, nattokinase degrades folded vWF independently of shear stress.
Ryuichi Hyakumoto   +3 more
wiley   +1 more source

Microbiome−host proteostasis crosstalk—An emerging perspective on mechanisms and interventions toward healthy longevity

open access: yesFEBS Letters, EarlyView.
Proteostasis and the gut microbiota play a key role in shaping host physiology. Microbiota‐derived metabolites, vitamins, and RNA modulate host proteostasis. Findings from model systems, including C. elegans, indicate microbes can either stabilize or disrupt host proteostasis.
Abhishek Anil Dubey, Maria Ermolaeva
wiley   +1 more source

Reporting Patterns Indicative of Adverse Drug Interactions

open access: yes, 2011
Background: Adverse drug interaction surveillance in collections of Individual Case Safety Reports (ICSRs) remains underdeveloped. Most efforts to date have focused on disproportionality analysis, but the empirical support for its value is based on ...
Bate, Andrew,   +12 more
core   +1 more source

A rat model of Immunologic and hypertensive kidney injury

open access: yesScientific Reports
Non-surgical rodent chronic kidney disease (CKD) models for both glomerular and tubular injuries are currently limited. The current study aimed to develop a rat model of CKD by combining anti-Fx1A with N(ω)-Nitro-L-Arginine Methyl Ester (L-NAME ...
Seo-Kyoung Hwang   +10 more
doaj   +1 more source

A peripherally restricted P2Y12 receptor antagonist altered rat tumor incidences with no human relevance: Mode of action consistent with dopamine agonism

open access: yesToxicology Reports, 2014
Background: Ticagrelor is an orally available, direct acting and reversible P2Y12 receptor antagonist approved for treatment of acute coronary syndrome.
David A. Brott   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy